SPECIFICITY OF COVID-19 INFECTION IN PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS
Abstract
During the Covid-19 pandemic, more than 858 million people worldwide have been infected with this virus, and over 6,4 million have died due to the infection. Similar to other infectious diseases, the implementation of personal hygiene, reduction of social contact, maintaining physical distance, and the isolation of infected patients are crucial in preventing the spread of the infection. However, the development of vaccines and active immunization are essential in preventing the spread of this highly contagious disease. Considering the health, sociological, and economic significance of the Covid-19 pandemic, various types of vaccines against the SARS-CoV-2 virus have been developed.
Patients undergoing maintenance hemodialysis (HD) are at an elevated risk of SARS-CoV-2 infection primarily due to frequent comorbidities, impaired immune system function, and the inability to reduce social contacts because of the necessity to attend the dialysis center at least three times a week. The efficacy and safety of vaccines against the SARS-CoV-2 virus have been investigated and evaluated in numerous studies involving the general population, while relatively few studies have been conducted among dialysis patients. According to current knowledge, dialysis patients exhibit a weaker and slower immune response to administered vaccines compared to individuals with preserved overall renal function. On the other hand, in the cohort of patients on maintenance hemodialysis, factors such as age, diabetes, and the use of immunosuppressive therapy contributed to the development of lower antibody titers against the SARS-CoV-2 virus after active immunization. Considering the vulnerability, exposure, and reduced resistance to infections in dialysis patients, it is crucial to administer vaccination against the SARS-CoV-2 virus in these patients.
References
Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From
the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239.
2. World Heath Organization. Coronavirus disease 2019 (COVID-19). Situation report – 51.
Accessed August 08, 2022. https://www.who.int/docs/default- source/coronaviruse/ situation-
reports/20200311-sitrep-51-covid19.pdf?sfvrsn=1ba62e57_10.
3. WHO Coronavirus (COVID-19) Dashboard. Accessed August 08, 2022.
https://covid19.who.int/.
4. Institut zа јаvnо zdrаvljе Srbiје „Dr Milаn Јоvаnоvić Bаtut”. Pristup sajtu 11.8.2022.g.
https://www.batut.org.rs/index.php?content=2026.
5. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for
the Treatment of Covid-19 — Final Report. N Engl J Med. 2020 Nov 5;383(19):1813–26.
6. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-
19. N Engl J Med. 2021 Feb 25;384(8):693–704.
7. Hayek S, Ben-shlomo Y, Dagan N, Reis BY, Barda N, Kepten E, et al. Effectiveness of
REGEN-COV antibody combination in preventing severe COVID-19 outcomes. Nat
Commun. 2022 Aug 2;13(1):4480.
8. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses,
Gorbalenya AE, Baker SC, Baric RS, De Groot RJ, Drosten C, et al. The species Severe acute
respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-
2. Nat Microbiol. 2020 Mar 2;5(4):536–44.
9. Brian DA, Baric RS. Coronavirus Genome Structure and Replication. In: Enjuanes L, editor.
Coronavirus Replication and Reverse Genetics [Internet]. Berlin, Heidelberg: Springer Berlin
Heidelberg; 2005 [cited 2023 Nov 25]. p. 1–30. (Current Topics in Microbiology and
Immunology; vol. 287). Available from: https://link.springer.com/10.1007/3-540-26765-4_1
10. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The
definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies
Conference report. Kidney Int. 2011 Jul;80(1):17–28.
11. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global
Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PloS One.
2016;11(7): e0158765.
12. Annual Reports [Internet]. ERA. [cited 2023 Nov 20]. Available from: https://www.era-
online.org/research-education/era-registry/annual-reports/
13. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. The Lancet.
2016 Jul;388(10041):276–84.
14. De Jager DJ. Cardiovascular and Noncardiovascular Mortality Among Patients Starting
Dialysis. JAMA. 2009 Oct 28;302(16):1782.
15. Agrawal S, Gollapudi P, Elahimehr R, Pahl MV, Vaziri ND. Effects of end-stage renal
disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine
production. Nephrol Dial Transplant. 2010 Mar 1;25(3):737–46.
16. Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, et al.
Immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015 Mar;9(2):84–96.
17. Johansen KL, Chertow GM, Foley RN, Gilbertson DT, Herzog CA, Ishani A, et al. US
Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United
States. Am J Kidney Dis. 2021 Apr;77(4): A7–8.
18. Hsu CM, Weiner DE, Aweh G, Miskulin DC, Manley HJ, Stewart C, et al. COVID-19
Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider.
Am J Kidney Dis. 2021 May;77(5):748-756.e1.
19. De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS, et
al. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement
Therapy: A Regionwide Registry Study. J Am Soc Nephrol. 2021 Feb;32(2):385–96.
20. Clarke C, Prendecki M, Dhutia A, Ali MA, Sajjad H, Shivakumar O, et al. High
Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using
Serologic Screening. J Am Soc Nephrol. 2020 Sep;31(9):1969–75.
21. Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate
dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action.
Kidney Int. 2021 Apr;99(4):791–3.
22. American Society of Nephrology. Prioritizing COVID-19 Vaccination in Dialysis.
Available online: https://www.kidneynews.org/view/news/policy-advocacy/leading-
edge/prioritizing-covid-19-vaccination-in-dialysis.xml [accessed on 1 June 2021].
23. Combe C, Kirsch AH, Alfano G, Luyckx VA, Shroff R, Kanbay M, et al. At least 156
reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis.
Nephrol Dial Transplant. 2021 Mar 29;36(4):571–4.
24. Garcia P, Montez-Rath ME, Moore H, Flotte J, Fults C, Block MS, et al. SARS-CoV-2
Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. J Am Soc Nephrol.
2021 Jul;32(7):1575–81.
25. Yadav T, Kumar S, Mishra G, Saxena SK. Tracking the COVID-19 vaccines: The global
landscape. Hum Vaccin Immunother. 2023 Dec 31;19(1):2191577.
26. World Health Organization. COVID-19 vaccine tracker and landscape. Available online:
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
[accessed on 4 July 2021].
27. World Health Organization. COVID-19 vaccine tracker and landscape. 2022. [accessed
2022 Dec 30] https://www.who.int/publications/m/item/draft-landscape-of-covid-19-
candidate-vaccines.
28. Basta NE, Moodie EMM. on behalf of the VIPER (Vaccines, infectious disease
prevention, and epidemiology research) Group COVID-19 vaccine development and
approvals tracker team. COVID-19 vaccine development and approvals tracker. 2020.
[accessed 2022 Dec 30].
29. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-
covid-19/covid-19-vaccines-2023-2024
30. Hannah R; Mathieu E, Rodés-Guirao L, Cameron A, Giattino C, Ortiz-Ospina E, Hasell
J, Macdonald B, Beltekian D, Dattani S, Roser Max. Coronavirus Pandemic (COVID-19). Our
World in Data. [retrieved 2024 January 27] https://ourworldindata.org/coronavirus
31. Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Tyczynski B, et al.
Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in
Patients on Hemodialysis. Vaccines. 2021 Apr 8;9(4):360.
32. Miyazaki, R., Miyagi, K., Yoshida, M. et al. Robust antibody response after the third
mRNA coronavirus vaccination in Japanese hemodialysis patients. Ren Replace Ther. 2023,
9, 38 (2023).
33. El-Hameed AA, Ahmed MF, Ehmemeed AOA, Mokhtar A, Abdelhamid WAR.
Assessment of humoral immune response to different COVID-19 vaccines in patients
undergoing maintenance hemodialysis. J Bras Nefrol. 2023 Oct-Dec;45(4):417-423.